| pubmed-article:3723987 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C0278695 | lld:lifeskim |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C0047506 | lld:lifeskim |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:3723987 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:3723987 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:3723987 | pubmed:dateCreated | 1986-8-20 | lld:pubmed |
| pubmed-article:3723987 | pubmed:abstractText | At four involved hospitals 16 children were treated with Metaiodobenzylguanidine (131J-MIBG). These children had a relapse of neuroblastoma stage III or IV or did not respond sufficiently to chemotherapy. In 10 children extreme bone pain disappeared and they became free of fever during the MIBG-treatment. 10 children responded to the therapy demonstrated either by decrease of the solid tumor part or by decrease of catecholamines in urine or plasma or by decrease of bone-marrow involvement. One patient reached a complete remission continuing up to present time (longer than 180 days). 9 patients died meanwhile of tumor progression. 131J-MIBG is an effective instrument, to get a decrease of the tumor up to a complete remission in extensively pretreated patients with tumor relapse, which are refractory to chemotherapy. | lld:pubmed |
| pubmed-article:3723987 | pubmed:language | ger | lld:pubmed |
| pubmed-article:3723987 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3723987 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3723987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3723987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3723987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3723987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3723987 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3723987 | pubmed:issn | 0300-8630 | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:NiethammerDD | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:FischerMM | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:GahrMM | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:SchwabeDD | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:Müller-Schaue... | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:FeineUU | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:MaulF DFD | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:KlingebielTT | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:GereinVV | lld:pubmed |
| pubmed-article:3723987 | pubmed:author | pubmed-author:KrazKK | lld:pubmed |
| pubmed-article:3723987 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3723987 | pubmed:volume | 198 | lld:pubmed |
| pubmed-article:3723987 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3723987 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:3723987 | pubmed:pagination | 230-6 | lld:pubmed |
| pubmed-article:3723987 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:meshHeading | pubmed-meshheading:3723987-... | lld:pubmed |
| pubmed-article:3723987 | pubmed:articleTitle | [Initial experiences in the treatment of children with metastatic and recurrent neuroblastoma using meta-iodobenzylguanidine]. | lld:pubmed |
| pubmed-article:3723987 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3723987 | pubmed:publicationType | English Abstract | lld:pubmed |
